Beam Therapeutics
BEAM
Beam Therapeutics (BEAM) earnings history
Most recent quarter
- Fiscal period
- Q4 2025
- Period end
- Dec 31, 2025
- EPS actual
- $2.33
- EPS estimate
- −$0.94
- EPS surprise
- +348.45%
- Revenue surprise
- +868.07%
- Revenue
- $114.1M
- Revenue estimate
- $11.8M
- Reported
- Feb 24, 2026
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q4 2025 | Feb 24, 2026 | −$0.94 | $2.33 | +348.45% | $114.1M | SEC |
| Q2 2025 | Aug 5, 2025 | −$1.11 | −$1.00 | +10.12% | $8.5M | SEC |
| Q1 2025 | May 6, 2025 | −$1.18 | −$1.24 | −4.75% | $7.5M | SEC |
| Q4 2024 | Feb 25, 2025 | −$1.23 | −$1.09 | +11.27% | $30.1M | SEC |
| Q3 2024 | Nov 5, 2024 | −$1.18 | −$1.17 | +1.12% | $14.3M | SEC |
| Q2 2024 | Aug 6, 2024 | −$1.13 | −$1.11 | +1.52% | $11.8M | SEC |
| Q1 2024 | May 7, 2024 | −$1.42 | −$1.21 | +14.50% | $7.4M | SEC |
| Q4 2023 | Feb 27, 2024 | −$0.69 | $1.73 | +350.29% | $316.2M | SEC |
| Q3 2023 | Nov 8, 2023 | −$1.33 | −$1.22 | +8.18% | $17.2M | SEC |
| Q2 2023 | Aug 8, 2023 | −$1.42 | −$1.08 | +24.19% | $20.1M | SEC |
| Q1 2023 | May 10, 2023 | −$1.32 | −$1.33 | −0.75% | $24.2M | SEC |
| Q4 2022 | Feb 28, 2023 | −$1.36 | −$0.54 | +60.22% | $20.0M | SEC |
| Q3 2022 | Nov 7, 2022 | −$1.26 | −$1.56 | −23.41% | $15.8M | SEC |
| Q2 2022 | Aug 9, 2022 | −$1.12 | −$1.02 | +8.95% | $16.7M | SEC |
| Q1 2022 | May 9, 2022 | −$0.89 | −$1.01 | −13.25% | $8.4M | SEC |
| Q4 2021 | Feb 28, 2022 | −$0.95 | −$0.95 | −0.21% | $51.1M | SEC |
| Q3 2021 | Nov 8, 2021 | −$0.72 | −$0.42 | +42.03% | $763,000.00 | SEC |
| Q2 2021 | Aug 10, 2021 | −$0.64 | −$1.23 | −93.52% | $6,000.00 | SEC |
| Q1 2021 | May 11, 2021 | −$0.74 | −$3.35 | −353.44% | $6,000.00 | SEC |
| Q4 2020 | Mar 15, 2021 | −$0.66 | −$1.69 | −154.94% | $6,000.00 | SEC |
Quarterly revenue
Frequently asked questions
When did Beam Therapeutics (BEAM) last report earnings?
Beam Therapeutics last reported on Feb 24, 2026, covering fiscal Q4 2025.
Did BEAM beat earnings estimates?
Yes. Beam Therapeutics reported EPS of $2.33 for Q4 2025 against a −$0.94 estimate — a 348.45% beat.
How much revenue did BEAM report last quarter?
Beam Therapeutics reported $114.1M in revenue for Q4 2025, against a consensus estimate of $11.8M.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.